Meeting News CoverageVideo

VIDEO: Time to MRD negativity predicted EFS in certain patients with ALL

ORLANDO, Fla. — Ryan D. Cassaday, MD, provides an overview of a study presented at the ASH Annual Meeting and Exposition in which he and colleagues determined earlier time to minimal residual disease negativity predicted longer EFS among adults with acute lymphoblastic leukemia treated with the hyper-CVAD regimen.

ORLANDO, Fla. — Ryan D. Cassaday, MD, provides an overview of a study presented at the ASH Annual Meeting and Exposition in which he and colleagues determined earlier time to minimal residual disease negativity predicted longer EFS among adults with acute lymphoblastic leukemia treated with the hyper-CVAD regimen.

    See more from ASH Annual Meeting and Exposition